Stock A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
109,000 KRW +0.37% Intraday chart for Daewoong Pharmaceutical Co., Ltd +5.72% -6.68%
May. 14 Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT

Strengths

  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in debt and has limited leeway for investment
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DAEWOONG PHARMACEUTICAL CO., LTD Stock Daewoong Pharmaceutical Co., Ltd
-6.68% 915M -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.64% 42.33B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+21.25% 22.47B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+18.92% 15.25B -
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+53.19% 12.6B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.11% 6.71B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.27% 5.47B
B+
GEDEON RICHTER Stock Gedeon Richter
+6.91% 4.78B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A069620 Stock
  4. Ratings Daewoong Pharmaceutical Co., Ltd